Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ustekinumab meets psoriasis endpoint

Johnson & Johnson (JNJ) said 67% and 76% of patients receiving 45 and 90 mg of

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE